To further define how these early kinetics of IFNβ modulates the T cell response later on during the therapeutic response, we dosed tumours with either recombinant murine IFNβ for 6 days (chronic) or for 3 days followed by an anti-IFNβ antibody (on/off), and analysed tumours by flow cytometry. Here, IFNB1 is linked to neoplasm.